CMPS

What one share of Compass Pathways holds

Pharmaceutical Preparations

We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments.

Compass Pathways’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Profit−$3.61
Cash and investments$3.19
Debt$0.37
Book value$0.62

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2019—−$2.62$0.02−$2.40—−$4.06
2020—−$3.55$0.01−$2.44——
2021—−$1.79$0.01−$1.70—$6.77
2022—−$2.16$0.01−$2.50—$4.24
2023—−$2.32$0.00−$1.91—$3.64
2024—−$2.30$0.00−$1.77—$2.26
2025—−$3.08———−$0.55

Common questions about Compass Pathways

How much does one share of Compass Pathways earn?

Over the last 12 months, Compass Pathways lost $3.61 for each share.

Does Compass Pathways pay a dividend?

Compass Pathways didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is Compass Pathways’s book value per share?

Compass Pathways’s book value is $0.62 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of Compass Pathways have?

Each share of Compass Pathways has $3.19 of cash and investments and $0.37 of debt, as of June 30, 2026.

Has Compass Pathways bought back shares?

Compass Pathways’s share count rose about 1151% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.